0.7297

1.03% -0.0076

After Hours: .7003 -0.0294 -4.03%

Biora Therapeutics Inc (BIOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Biora Therapeutics Inc stock is currently priced at $0.7297, with a 24-hour trading volume of 220.01K. It has seen a -1.03% decreased in the last 24 hours and a +13.64% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.7221 pivot point. If it approaches the $0.7617 resistance level, significant changes may occur.

Previous Close:

$0.7373

Open:

$0.74

24h Volume:

220.01K

Market Cap:

$26.18M

Revenue:

$98,000

Net Income/Loss:

$-122.42M

P/E Ratio:

-0.1339

EPS:

-5.45

Net Cash Flow:

$-45.88M

1W Performance:

-0.42%

1M Performance:

+13.64%

6M Performance:

-46.35%

1Y Performance:

-78.02%

1D Range:

$0.7001

$0.75

52W Range:

$0.585

$6.70

Biora Therapeutics Inc Stock (BIOR) Company Profile

Name

Biora Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

855 293 2639

Address

4330 La Jolla Village Drive, Suite 300, San Diego

Employee

124

Twitter

Next Earnings Date

2024-06-05

Latest SEC Filings

BIOR's Discussions on Twitter

Biora Therapeutics Inc Stock (BIOR) Latest News

BIOR: BT-600 Data in June - Yahoo Finance

Yahoo Finance

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - GlobeNewswire

GlobeNewswire

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

GlobeNewswire Inc.

Biora Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview - XM

Biora Therapeutics (BIOR) to Release Quarterly Earnings on Wednesday - Defense World

Defense World

Biora Therapeutics Inc Stock (BIOR) Financials Data

Biora Therapeutics Inc (BIOR) Revenue 2024

BIOR reported a revenue (TTM) of $98.00 thousand for the quarter ending June 30, 2023, a -88.16% decline year-over-year.

Biora Therapeutics Inc (BIOR) Net Income 2024

BIOR net income (TTM) was -$122.42 million for the quarter ending September 30, 2023, a -4.36% decrease year-over-year.

Biora Therapeutics Inc (BIOR) Cash Flow 2024

BIOR recorded a free cash flow (TTM) of -$45.88 million for the quarter ending September 30, 2023, a +51.28% increase year-over-year.

Biora Therapeutics Inc (BIOR) Earnings per Share 2024

BIOR earnings per share (TTM) was -$9.59 for the quarter ending September 30, 2023, a +44.60% growth year-over-year.

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.